Clinical research of Yiqi Sanju Formula in treating central obese men at high risk of metabolic syndrome
Authors:
- Wen-Jian WangWWWen-Jian Wang
- Bin LiBLBin Li
- De-Sheng XuDXDe-Sheng Xu
- Wei-Hua ChenWCWei-Hua Chen
- Jiang YingJYJiang Ying
- Yan-Ming HeYHYan-Ming He
- 15 May 2007
- journal article
- research article
- Published by Journal of Chinese Integrative Medicine Press in Journal of Chinese Integrative Medicine
- Vol. 5 (3) , 263-267
Abstract
To observe the therapeutic effects of Yiqi Sanju Formula (YQSJF), a compound Chinese herbal medicine, on central obese men at high risk of metabolic syndrome (MS). Compared with 30 healthy male volunteers, 45 central obese men were separated randomly into two groups and received the interventions with YQSJF and placebo respectively for 10 weeks. Baseline characteristics, insulin resistance, inflammation cytokines and plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (t-PA) were evaluated before and after treatment. The score of homeostatic model assessment for insulin resistance (HOMA-IR) and the levels of C reactive protein (CRP), free fatty acid (FFA) and PAI-1 in obese men were higher than those in the control group, while t-PA was lower. After treatment, compared with placebo group, body mass index, waist, and waist-to-hip ratio were decreased significantly in subjects who received YQSJF (P<0.01). The score of HOMA-IR and the levels of CRP, FFA and PAI-1 were decreased significantly, and the level of t-PA was increased significantly (P<0.01). YQSJF can reduce obesity and insulin resistance in central obese men at high risk of MS and improve inflammation and fibrinolysis, which indicates that it can reduce the risk of atherosclerosis.Keywords
This publication has 11 references indexed in Scilit:
- Foundation and application of aggregation syndrome theory in traditional Chinese medicineJournal of Chinese Integrative Medicine, 2007
- PAI-1 and the Metabolic SyndromeArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 DiabetesDiabetes, 2006
- Fatty acid—induced inflammation and insulin resistance in skeletal muscle and liverCurrent Diabetes Reports, 2006
- C-reactive protein is elevated in obese patients with the metabolic syndromeDiabetes Research and Clinical Practice, 2006
- Plasminogen Activator Inhibitor-1 and Tissue-Plasminogen Activator in Minority Adolescents with Type 2 Diabetes and ObesityPediatric Research, 2005
- Does C‐reactive protein identify a subclinical metabolic disease in healthy subjects?European Journal of Clinical Investigation, 2005
- Hypercoagulability in the metabolic syndromeCurrent Opinion in Pharmacology, 2005
- Inverse relationship between plasminogen activator inhibitor-1 activity and adiponectin in overweight and obese womenThrombosis and Haemostasis, 2005
- Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetesMetabolism, 2002